Latest Trends and Research Released on Alzheimer's Disease by Academic and Biotech Industry Scientists
NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- The 10th International Conference on Alzheimer's Drug Discovery, hosted by the Alzheimer's Drug Discovery Foundation and the only scientific conference focusing solely on the discovery and development of innovative drugs targeting Alzheimer's disease and related dementias, will convene September 14-15, 2009 at the Hyatt Regency in Jersey City, N.J.
More than 30 leading international experts from academia and early-stage biotechnology companies will present and discuss their most current research. The meeting draws an audience of academic and industry scientists engaged in drug discovery research for neurodegenerative diseases. Because of ADDF's venture philanthropy focus, the conference is also open to business development and licensing professionals, alliance management professionals, venture capitalists, and other investors in biotechnology.
"We are proud to feature the accomplishments of our funded investigators and other researchers working on innovative approaches to drug discovery for Alzheimer's disease and related dementias," says Howard Fillit, MD, Executive Director of Alzheimer's Drug Discovery Foundation. "Our sole focus is accelerating the discovery of effective new treatments for Alzheimer's disease- bridging the gap that currently exists between basic research and later-stage drug development.
The conference program will focus on four major areas of study:
Neuroprotection and Prevention
Chair: Dr. Frank Longo, MD, PhD, Stanford University
Anti-Amyloid and Protein Misfolding
Chair: Michael Wolfe, PhD, Brigham and Women's Hospital
Anti-Tangles and Frontotemporal Dementia
Chair: Jeff Kuret, PhD, Ohio State University
Alternative Strategies: New Targets for Alzheimer's Disease Therapy
Chair: Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation
The program will feature two plenary sessions: "Bridging Neurocognitive Aging and Disease Modification," by Michaela Gallagher, PhD, Johns Hopkins; and "TDP-43 as a New Target for Neurodegenerative Disease," by Virginia Lee, PhD, MBA, University of Pennsylvania.
The Alzheimer's Drug Discovery Foundation will also present the 2009 ADDF Young Investigators Scholarships, highly prestigious scholarships recognizing the early research achievements of ten younger scientists from academia.
The 10th International Conference on Alzheimer's Drug Discovery is sponsored by Pfizer Inc.; Elan Pharmaceuticals; Martek Biosciences Corporation; Schering-Plough; Allon Therapeutics, Inc.; JSW Lifesciences; Abbott; The American Journal of Geriatric Pharmacotherapy; Apredica; Intra-Cellular Therapies, Inc.; and Rhenovia Pharma.
For Conference Participants: To view the complete program schedule, to apply to register for the conference, and for information on accommodations, visit www.alzdiscovery.org.
About the Alzheimer's Drug Discovery Foundation
ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. We award grants to leading scientists conducting breakthrough drug discovery research. ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research. Since 1998, we have received over 1,600 requests to fund new ideas for Alzheimer's drugs. For all, we provided expert reviews and recommendations to advance their programs. We granted more than $35 million to fund more than 240 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 12 countries. The ADDF Website carries the latest, vetted news on Alzheimer's disease, updated weekly.
|SOURCE Alzheimer's Drug Discovery Foundation|
Copyright©2009 PR Newswire.
All rights reserved